Pharmaceutical Patent Infringement in India: Key Lessons from Beone Medicines vs. MSN Laboratories

On October 16, 2026, the Delhi High Court took on record an undertaking from MSN Laboratories in a patent dispute concerning zanubrutinib. BeOne Medicines I GmbH had filed the case, CS(COMM) 1144/2026 and asked the court for urgent relief against MSN’s supply and sale of the drug. MSN agreed not to supply or sell zanubrutinib in India or abroad, except for activities allowed under Section 107A of the Patents Act. 

The court bound MSN to that promise and sent the parties to mediation to explore a settlement. The order does not decide infringement. Still, it shows how such disputes involve interim restrictions, generic drug supply and the research exemption under Indian patent law.

Understanding the BeOne Medicines v. MSN Laboratories Patent Dispute

BeOne Medicines, which was previously called BeiGene, works on developing cancer treatments. One of them is zanubrutinib, sold as BRUKINSA. MSN Laboratories is an Indian company that makes generic and other pharmaceutical products. The two have met in court before. 

BeOne’s own records show it sued MSN over generic zanubrutinib in the United States and settled that case in 2024. The Indian proceedings therefore bring the parties’ earlier dispute into a different legal setting, with the Delhi High Court considering BeOne’s request for interim protection under Indian patent law. 

Also Read: Comcast Hit with $213 Million Patent Infringement Verdict

The Role of Patents in Protecting Zanubrutinib (BRUKINSA)

Zanubrutinib is a BTK inhibitor used in cancer treatment and it is sold as BRUKINSA. Patents matter here because they protect the years of work behind a medicine. Those rights can give the patent holder a period of legal protection against products that fall within the scope of the asserted claims, subject to the limits and exceptions under patent law. One medicine often carries several patents, covering the composition, crystalline forms, formulation, manufacturing or therapeutic use. 

In BeOne’s earlier U.S. litigation, MSN challenged certain BRUKINSA patents but did not challenge the composition-of-matter patent. That history shows how layered these disputes can be. It does not tell us which patents are involved in the Indian case, as that depends on the pleadings and the order.

The Delhi High Court Order Issued on October 16, 2026

In its October 16, 2026 order, the Delhi High Court noted a statement made by MSN Laboratories. MSN said it would not supply or sell zanubrutinib to anyone in India or abroad. The only exception was for activities allowed under Section 107A of the Patents Act, 1970. 

MSN also promised to ensure and establish that any such activity was genuinely linked to research and development and regulatory submission requirements. The court took the statement on record and bound MSN to it. It then disposed of BeOne’s interim-injunction application on those terms. 

The October 16 order does not amount to a final determination of infringement; it records the defendant’s undertaking in the context of BeOne’s request for interim relief. That difference matters when reading the outcome. 

How Section 107A Shapes Generic-Drug Activity in India?

Section 107A of the Patents Act, 1970 works as a research and regulatory exception. In broad terms, some acts involving a patented invention fall outside infringement when they are done to develop or generate information or to meet regulatory requirements and submit information to authorities. So a patented drug does not necessarily block every activity involving it before the patent expires. This matters in BeOne’s case.

MSN did not simply promise to stay away from zanubrutinib. It promised not to supply or sell the drug while keeping activities that fall under Section 107A, subject to the conditions recorded by the court. 

The order also referred to the Delhi High Court’s earlier decision in Bayer Corporation v. Union of India, 2019 SCC OnLine Del 8209, in connection with those activities. That reference adds a legal layer to the story, linking this dispute to how Indian courts have approached Section 107A in pharmaceutical patent enforcement. 

Why Does an Interim Injunction Matter in Pharmaceutical Patent Litigation?

Interim relief is meant to protect a party’s position while the larger dispute continues. In pharmaceutical cases timing matters. If a generic product enters the market too early, it can affect sales, market share, pricing, patient access and commercial exclusivity. Waiting for a full trial may take years and some of that damage is hard to undo. 

The case illustrates why interim relief can be commercially important even before the court decides the underlying patent claims. By recording MSN’s undertaking, the court placed temporary limits on commercial supply while allowing the dispute to proceed through the ordinary litigation process. The practical effect at this stage was therefore to regulate MSN’s conduct while the underlying patent dispute continued.

What Generic Manufacturers Can Learn from the BeOne-MSN Case

Generic companies need to weigh patent risk before they launch or supply a product. That assessment should cover the relevant patent claims, their status and remaining term, the scope of the proposed product and any statutory provisions that could affect the planned activity. The BeOne-MSN order shows why these questions matter. 

MSN’s undertaking separated commercial supply and sale from activities that may fall within a statutory exception. The key question is whether the particular activity falls within the statutory exception and the conditions that govern it. The line depends on what the activity is and why it is being done.

Also Read: Anthropic Faces Music Publishers in AI Copyright Dispute

Key Lessons for Pharmaceutical Companies and Patent Owners

The BeOne–MSN order is an early-stage development yet it points to clear lessons for pharmaceutical companies and patent owners. The key ones are outlined below.

• Patent holders should look at commercial risks early and decide whether interim protection may be needed while an infringement dispute is pending.
• Pharmaceutical companies should be clear about what their patents actually protect and whether a competing product or process falls within the asserted claims.
• Patent rights need to be considered together with exceptions such as Section 107A, which can determine whether certain research and regulatory activities are permitted.
• Following generic development, regulatory activity, patent expiry and likely market entry allows owners to deal with infringement risks on time.
• Enforcement, market timing, regulatory requirements and likely competitor conduct should be considered together when planning IP strategy.

The Role of Patent Claims in Pharmaceutical Infringement 

In a pharmaceutical infringement case, the court must connect the language of the asserted patent claims with the accused product or process. That analysis determines whether the competing product falls within the legal scope of the patent. The question is not simply whether two medicines treat the same disease. Many drugs do and that alone proves nothing. 

For pharmaceutical patent holders, the practical question is not merely whether a competing medicine resembles the patented product, but whether the competitor’s product or process falls within the legal scope of the asserted claims. 

What Happens Next in the BeOne–MSN Case?

The case is still at an early stage. Under the October 16 order, the pleadings will continue and the matter was listed for completion of pleadings and admission and denial of documents. The court referred the parties to mediation to explore the possibility of an amicable settlement. The order does not establish that a settlement has been reached. 

The case was listed for February 2, 2027 for framing of issues and for reporting of any settlement. The February 2027 hearing will therefore be an important next procedural stage in the dispute. 

The BeOne–MSN dispute highlights how pharmaceutical patent litigation can involve several legal questions at once, from the scope of patent rights to the limits of interim protection and statutory exceptions. For pharmaceutical companies, effective patent strategy therefore requires attention not only to enforcement but also to timing, generic competition and the statutory boundaries of patent exclusivity. 

For generic manufacturers the case also shows why launch planning needs to account for both patent risk and the legal framework governing pre-market activities.